Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix
Public ClinicalTrials.gov record NCT00003017. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Clinical Trial of Interleukin-12 in Patients With Advanced, Recurrent or Inoperable Carcinoma of the Cervix
Study identification
- NCT ID
- NCT00003017
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- recombinant interleukin-12 Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 30, 1997
- Primary completion
- Not listed
- Completion
- Jul 31, 2005
- Last update posted
- Jun 20, 2013
1997 – 2005
United States locations
- U.S. sites
- 9
- U.S. states
- 5
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Hunterdon Regional Cancer Center | Flemington | New Jersey | 08822 | — |
| CCOP - Northern New Jersey | Hackensack | New Jersey | 07601 | — |
| NYU School of Medicine's Kaplan Comprehensive Cancer Center | New York | New York | 10016 | — |
| University of Rochester Cancer Center | Rochester | New York | 14642 | — |
| Albert Einstein Comprehensive Cancer Center | The Bronx | New York | 10461 | — |
| Fox Chase Cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| University of Pittsburgh Cancer Institute | Pittsburgh | Pennsylvania | 15213 | — |
| Vanderbilt Cancer Center | Nashville | Tennessee | 37232-6838 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00003017, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 20, 2013 · Synced Jul 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00003017 live on ClinicalTrials.gov.